WHO issues global guideline on the use of GLP-1 medicines in treating obesity
1 December 2025
To address the growing global health challenge of obesity, which affects more than 1 billion people, the World Health Organization (WHO) has released its first guideline on the use of Glucagon-Like Peptide-1 (GLP-1) therapies for treating obesity as a chronic, relapsing disease.
Obesity affects people in every country and was associated with 3.7 million deaths worldwide in 2024. Without decisive action, the number of people with obesity is projected to double by 2030.
“Obesity is a major global health challenge that WHO is committed to addressing by supporting countries and people worldwide to control it, effectively and equitably. Our new guidance recognizes that obesity is a chronic disease that can be treated with comprehensive and lifelong care,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.
Obesity is a complex, chronic disease and a major driver of noncommunicable diseases, such as cardiovascular diseases and type 2 diabetes and some types of cancer. It also contributes to poorer outcomes of patients who have infectious diseases.
Obesity affects people in every country and was associated with 3.7 million deaths worldwide in 2024. Without decisive action, the number of people with obesity is projected to double by 2030.
Key facts
•In 2022, 1 in 8 people in the world were living with obesity.
•Worldwide adult obesity has more than doubled since 1990, and adolescent obesity has quadrupled.
•In 2022, 2.5 billion adults (18 years and older) were overweight. Of these, 890 million were living with obesity.
•In 2022, 43% of adults aged 18 years and over were overweight and 16% were living with obesity.
•In 2024, 35 million children under the age of 5 were overweight.
•Over 390 million children and adolescents aged 5–19 years were overweight in 2022, including 160 million who were living with obesity.
Medical Treatment Now Recognised
For the first time, WHO has issued global guidance supporting the use of GLP-1 medications (including Ozempic, Wegovy, Mounjaro) as part of long-term obesity care under medical supervision, alongside diet and physical activity.
Not a Quick Fix
WHO notes that medication alone is not a cure.
Obesity requires ongoing management, lifestyle adjustment, and structured follow-ups with healthcare providers.
What This Means for Patients
Adults struggling with weight now have internationally recognized medical options.
Treatment should be personalized, professionally monitored, and viewed like any other long-term health condition—such as diabetes or hypertension.
Interested in Learning More?
If you’re considering medical weight-management options, you are welcome to book a consultation or walk in to speak with our doctor first.
Our team will review your health, discuss suitable treatment steps, and answer any questions before you begin.
GLP-1 medications, including Mounjaro, are available at MedConsult Clinic under licensed medical supervision.
Doctor’s Profile
Dr. Donna Robinson, Medical Director and British GP, has over 20 years of experience in diagnosing and treating chronic conditions including obesity, diabetes risk, and metabolic issues. She provides a holistic approach to weight management, focusing on safe and medically appropriate treatment plans.
Dr. Pui, our psychiatrist, also supports patients whose weight challenges are linked to stress, emotional eating, anxiety, or depression. Her integrative approach helps patients address the mental and emotional components of obesity, leading to more sustainable long-term results.
Final Thoughts
Obesity is a medical condition influenced by multiple factors — not a matter of willpower. Understanding the underlying causes, receiving proper assessment, and making gradual changes can significantly reduce long-term health risks.
If you have struggled with weight management, slow metabolism, cravings, or repeated unsuccessful attempts to lose weight, seeking structured guidance can make the process smoother and more effective.
Frequently Asked Questions (FAQs)
Is obesity just about appearance?
No. Obesity is a medical condition involving excess fat accumulation and increased health risks.
Is BMI an accurate measurement?
BMI is a screening tool, not a perfect measure. Body composition, waist size, and metabolic health also matter.
Can obesity be caused by hormones?
Yes. Thyroid disorders, PCOS, menopause, and cortisol imbalance can all contribute.
Why do some people gain weight even when eating “normally”?
Metabolic rate, genetics, stress, poor sleep, and certain medications all play a role.
Learn More About Medical Weight-Loss Options
For individuals who want a more guided and structured approach to weight reduction — including medical assessment, personalised recommendations, and strategic weight-management methods — you can explore MedConsult’s dedicated Weight-Loss Program page here: